LevodopaMarket by Application (Parkinson’s disease and Dopamine ResponsiveDystonia), by Drug Type (Rytary, Duopa, Sinemet, Canamet, and Others), byDistribution Channels (Hospital Pharmacies, Retail Pharmacies, and OnlinePharmacies) and by Geography (North America, Europe, Asia Pacific, LatinAmerica, Middle East, and Africa) - Size, Share, Outlook, and OpportunityAnalysis 2018 – 2026.
Levodopa or L-Dopa is a chemicalbuilding-block that converts into a dopamine in body. Dopamine is the chemicalmessenger released in brain. It mediates pleasure, cognition, and memoryfunctions. Nearly all patients receive the dopamine precursor levodopa, whichadequately control symptoms of Parkinson's disease (PD) at early stage of thedisease. Carbidopa is often included with levodopa-containing drugs in order toboost its efficacy by slowing down the metabolism of dopamine.
Levodopa Market Driver
Development of novel formulationsand efficient drug delivery methods for levodopa are expected to drive growthof the levodopa market. For instance, a clinical study for gastric retentiveAccordion Pill, an immediate drug release formulation by Intec Pharma Ltd., isongoing in clinical phase III and is expected to complete in September 2018.Accordion Pill is a Carbidopa/Levodopa (AP-CD/LD) combinational oral drugdelivery system, which is designed to improve the efficacy and safety ofexisting CD/LD drugs by utilizing an efficient gastric retention and specificrelease mechanism.
* The sample copy includes:Report Summary, Table of Contents, Segmentation, Competitive Landscape, ReportStructure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2247
Moreover, Impel NeuroPharma Inc.is conducting phase II clinical study for INP103, a drug-device combinationproduct containing a drug component, L-dopa, and device component I231Precision Olfactory Delivery (POD) device. The study is expected to complete inNovember 2018.
Furthermore, advancement indiagnosis of Parkinson's disease (PD) progression is expected to boost growthof levodopa market. For instance, a clinical study conducted by WashingtonUniversity School of Medicine, for measuring PD progression both by usingMagnetic Resonance Imaging (MRI) and by controlled dose of levodopa fordiscovering suitable biomarker of PD is currently in clinical phase I and isexpected to complete in February 2019.
Levodopa Market Restraint
Shortage of drug supply in themarket due to delay in manufacturing and supply of levodopa is expected tohamper levodopa market growth. For instance, Merck Sharp & Dohme Ireland(Human Health) Ltd. in September 2018, anticipated stock shortage of someSinemet (Carbidopa/ Levodopa) products in the Irish market in near future dueto global manufacturing delays in production and demand for resupply of theseproducts.
Levodopa Market – RegionalAnalysis
On the basis of region, theglobal levodopa market is segmented into North America, Latin America, Europe,Asia Pacific, Middle East, and Africa.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/levodopa-market-2247
North America is expected todominate the global levodopa market, owing to approval of new products by the U.S.Food and Drug Administration (FDA). For instance, in 2015, FDA approved anextended-release oral formulation of Levodopa/Carbidopa called Duopa,manufactured by AbbVie Inc., in the U.S. market. Duopa is a gel formulation ofCarbidopa/Levodopa enteral suspension and is administered using a small,portable infusion pump that delivers Carbidopa and Levodopa directly into thesmall intestine, which continuously release over 16 hours in the body.
Europe region is expected towitness significant growth in levodopa market due to involvement of key playersfor marketing novel formulations in European region. For instance, AcordaTherapeutics, Inc., in March 2018, submitted a Marketing AuthorizationApplication (MAA) to the European Medicines Agency (EMA) for INBRIJA, aninvestigational inhaled levodopa treatment for symptoms of OFF periods (OFFsymptoms implies recurrence of symptoms such as rigidity, and tremors afterlong period of levodopa use) in people with PD taking a Carbidopa/Levodoparegimen.
Furthermore, in November 2015,Impax Laboratories, Inc. received European Commission (EC) marketingauthorization for NUMIENT (Levodopa and Carbidopa), a modified-release oralcapsule formulation for the symptomatic treatment of adult patients withParkinson's disease in Europe region.
The key players operating inlevodopa market include, Taj Pharmaceuticals Limited., Guangzhou HanFangPharmaceutical Company Limited, Poulvet.com, Teva Pharmaceutical IndustriesLtd., UBM, Zhejiang Wild Wind Pharmaceutical Co., Ltd., and SWAPNROOP.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2247
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
